Summary Bombesins are potent growth factors for murine Swiss 3T3 cells. Using these cells in chemically defined conditions we have been able to characterise the bombesin receptor and the early signals preceding DNA synthesis. We describe two substance P analogues [DArg1, DPro2, DTrp7 9, Leu1 ] substance P and [DArg1, DPhe5, DTrp7 9, Leu1'] substance P which competitively block the binding of bombesins to their receptor and all the events leading to mitogenesis. Bombesins are secreted by human small cell lung cancers (SCLC) and may act as autocrine growth factors for these tumours, so the development of peptide bombesin antagonists could have therapeutic implications. We demonstrate that the antagonists can reversibly inhibit the growth of SCLC in vitro, with relatively little effect on other lung tumours.
Growth factors are implicated in a wide variety of physiological and pathological processes including embryogenesis, haemopoiesis, wound healing, immune responses, atherosclerosis and neoplasia (Evered et al., 1985; Sporn & Roberts, 1986 ). An important link between growth factors and their receptors and oncogene products has also been established (Heldin & Westermark, 1984; Weinstein, 1987) . Thus, the elucidation of the mechanism of action of growth factors has emerged as one of the fundamental problems in biology and may prove crucial for understanding the unrestrained proliferation of cancer cells.
Many studies of growth factors have used cultured fibroblasts, such as 3T3 cells, as a model system. These cells cease to proliferate when they deplete the medium of its growth promoting activity. Such quiescent cells can be stimulated to reinitiate DNA synthesis and cell division either by replenishing the medium with fresh serum, or by the addition of growth factors or pharmacological agents in serum-free medium (Rozengurt, 1983) (Figure 1 ). Studies performed with combinations of growth factors have revealed an important aspect of their action: the existence of potent and specific synergistic interactions (Rozengurt, 1986) . This finding suggested that growth factors bind to different receptors, and generate multiple intracellular signals which interact synergistically to initiate a proliferative response.
A new and intriguing development is the discovery that neuropeptides such as bombesin, vasopressin, vasoactive intestinal peptide (VIP), and substance K can also act as growth factors for cells in culture (Figure 1 ). Bombesin-like peptides are potent mitogens for Swiss 3T3 cells (Rozengurt & Sinnett-Smith, 1983 ) and have attracted interest as possible autocrine growth factors for small cell lung cancer (SCLC). Here we summarize our recent studies using bombesin-like peptides for elucidating the signal transduction pathways leading to mitogenesis and lung bombesin antagonists in SCLC.
Bombesin
Bombesin is a tetradecapeptide first isolated from amphibian skin (Anastasi et al., 1971) . Struct-urally-related peptides (Table I) in amphibians and mammals are widely distributed, but found notably in the gut (e.g. gastrin-releasing peptide GRP) where they have secretory effects (McDonald et al., 1979; Lezoche et al., 1981) the neuromedins) where they may act as neurotransmitters (Minamino et al., 1983; 1985) .
Bombesin-like peptides are abundant in fetal lung (Wharton et al., 1978; Price et al., 1983; Yamaguchi et al., 1983) and the mRNA for GRP is maximally expressed at 16-30 weeks (Spindel et al., 1987) . Thereafter levels decline rapidly, and in adulthood these peptides are found sparsely in bronchial neuroendocrine cells. Speculation that bombesins may be growth factors for fetal lung has been supported by the paucity of expression in the immature lungs of infants with respiratory distress syndrome (Ghatei et al., 1983) .
Mitogenic response of Swiss 3T3 cells to bombesin
In serum-free medium, bombesin induces DNA synthesis and cell division in the absence of other growth-promoting agents with a half-maximal effect at 1 nM. The ability of bombesin, like-platelet-derived growth factors (PDGF), to act as a sole mitogen for Swiss 3T3 cells contrasts with other growth factors which are only active in synergistic combinations (Rozengurt, 1986) . The stimulation of DNA synthesis by bombesin is markedly potentiated by insulin. This hormone, probably acting in lieu of insulin-like growth factor-I (IGF1), both increases the maximal response elicited by (Zachary & Rozengurt, 1985a (Zachary & Rozengurt, 1987a (Masu et al., 1987 ).
Bombesin does not cause down-regulation of its receptor The binding of polypeptide growth factors such as EGF and PDGF to their receptors is followed by rapid internalization and intracellular degradation of the ligand and the receptor (James & Bradshaw, 1984; Goldstein et al., 1985) . This process results in a marked reduction in the number of surface binding sites in the target cells (down-regulation). In contrast, exposure of Swiss 3T3 cells to mitogenic concentrations of bombesins for different times up to 24h did not cause any significant change in the number of cell surface binding sites for these peptides . Furthermore, pretreatment with GRP did not cause either an alteration in the concentration dependence of binding of the labelled peptide or a reduction in the level of the Mr 75,000-85,000 surface protein component of the bombesin receptor.
It has been proposed that the internalisation and degradation of growth factor receptors and their ligands may have a signalling function in mitogenesis (King & Cuatrecasas, 1981; James & Bradshaw, 1984; Bergeron et al., 1985; Wakshull & Wharton, 1985) . The fact that the bombesins are able to stimulate DNA synthesis and trigger a wide variety of signalling events without reducing the number of their surface receptors suggests that extensive receptor down-regulation is not always an obligatory process in mitogenesis.
Early events elicited by bombesins
The binding of growth factors to their receptors promotes the generation of early signals in the membrane, cytosol and nucleus which lead to cell proliferation (Rozengurt, 1986) . Since the initiation of DNA synthesis occurs 10 to 15h after the addition of the mitogens, it is expected that knowledge of the early events will provide clues to primary regulatory mechanisms. These are summarized in Figure fluxes of Na+, K+ and H+ across the plasma membrane.
Bombesins stimulate a rapid influx of Na+ into Swiss 3T3 cells via an amiloride-sensitive Na+/H+ antiport (Mendoza et al., 1986) . This increases intracellular Na+ and causes cytoplasmic alkalinization. Since the activity of the Na+/K+ pump is regulated by intracellular Na+, there is a secondary stimulation of Na+/K+ pump activity which increases K+ and restores the electrochemical gradient for Na+. The ability of bombesin, like PDGF and other growth factors, to induce cytoplasmic alkalinization suggests that the activation of Na+/H+ exchange is a primary effect of the mitogens rather than a compensatory mechanism for the extrusion of protons resulting from a growth factor-induced acceleration of cellular metabolism.
In addition to rapid changes in monovalent ion fluxes, bombesins cause a rapid mobilization of Ca2+ from intracellular stores, which leads to a transient increase in the concentration of cytosolic Ca2` (Mendoza et al., 1986) . This Ca2+ flux is distinct from that caused by PDGF (LopezRivas et al., 1987) . The mobilization of Ca2`by bombesins and other mitogens may be mediated by inositol 1,4,5-trisphosphate (IP3), which has been proposed to act as a second messenger in the action of many ligands that stimulate phospholipase C-mediated inositol lipid turnover and Ca2`efflux (Berridge & Irvine, 1984) . IP3 is formed as a result of phospholipase C catalysed hydrolysis of phosphatidyl 4,5-bisphosphate (PIP2) in the plasma membrane, a process that also generates 1,2-diacylglycerol (DAG). Bombesins have been shown to cause enhanced inositol lipid metabolism in Swiss 3T3 cells leading to the formation of 1P3 (Heslop et al., 1985; Lopez-Rivas et al., 1987; Muir & Murray, 1987; Takuwa et al., 1987) .
Activation ofprotein kinase C Protein kinase C (which is stimulated by DAG) has received considerable attention because it is a major receptor for the tumour promoters of the phorbol ester family (Nishizuka, 1984) . Since phorbol esters and 1-oleoyl-2-acetylglycerol (OAG) can act as mitogens for quiescent cells, protein kinase C may play a role in the initiation of a proliferative response (Dicker & Rozengurt, 1980; Rozengurt et al., 1984) . The M, 80,000 cellular protein termed 80K has been shown to be a specific substrate of protein kinase C in intact cultured cells Bishop et al., 1985; Blackshear et al., 1985; Rodriguez-Pena & Rozengurt, 1986) . Although the nature and role of the 80K protein remain obscure, changes in its phosphorylation state provide a marker for protein kinase C activation in intact cells (Figure 2) .
Addition of bombesins causes a rapid (15 seconds) increase in 80K phosphorylation in quiescent Swiss 3T3 cells (Isacke et al., 1986; . Removal of the peptide results in rapid (half-life 90s) dephosphorylation of 80K. Prolonged. pretreatment (40 h) with PBt2 leads to the disappearance of measurable protein kinase C activity and prevents the increase in 80K phosphorylation by subsequent addition of phorbol esters, phospholipase C, or OAG (Rodriguez-Pena & Ballaster & Rosen, 1985; Stabel et al., 1987) . This treatment completely abolished the effect of bombesin on 80K phosphorylation . This inhibition can, however, be fully reversed by insulin. Thus, activation of protein kinase C represents one of the pathways through which bombesins can initiate cell proliferation. A number of growth factor receptors and retroviral oncogene products exhibit tyrosinespecific protein kinase activity. Whether or not bombesin stimulates tyrosine phosphorylation remains controversial (Isacke et al., 1986; Cirillo et al., 1986) .
Protein kinase C, ion fluxes and transmodulation of EGF receptor In addition to its role in stimulating cell division, protein kinase C may also be important in coordinating the network of early events triggered by bombesins. Activation of protein kinase C leads to increased activity of the Na+/H+ antiport system (Vara et al., 1985) . Stimulation of ion fluxes by bombesins is only partially inhibited, however, by PBt2 pretreatment suggesting that these peptides can stimulate Na+/H+ antiport activity by an alternative mechanism (dotted line, Figure 2) (Mendoza et al., 1986) . Protein kinase C activation can also inhibit Ca2+ mobilization, suggesting some feedback control (Lopez-Rivas et al., 1987) .
[12 5I]EGF binding to specific surface receptors in Swiss 3T3 cells is markedly inhibited by bombesins (Brown et al., 1984; ). The effect is rapid in onset and results from a decrease in the apparent affinity of the EGF receptor population for EGF. Considerable evidence implicates protein kinase C in the regulation of EGF receptor affinity by bombesin and other transmodulating agents (Zachary & Rozengurt, 1985b) : the inhibition of EGF binding induced by either PBt2 or bombesin is prevented by the removal of protein kinase C from the cells by prolonged treatment with phorbol esters; the EGF receptor is phosphorylated by protein kinase C at a specific site (Thr 654) both in vitro and in vivo (Lin et al., 1986) . Thus, transmodulation of the EGF receptor may result from the covalent modification of the EGF receptor catalysed by protein kinase C, though other mechanisms are not excluded.
Cyclic nucleotides A sustained increase in the intracellular level of cyclic AMP (cAMP) can act as a mitogenic signal for many cell types (Rozengurt, 1986) . Activation of protein kinase C either directly by PBt2 or by vasopressin (through receptors which are not directly coupled to adenylate cyclase), has recently been shown to enhance cAMP accumulation in Swiss 3T3 cells . We have found that bombesin also markedly potentiates the accumulation of cAMP caused by cAMP-elevating agents such as forskolin, an effect mediated at least in part by protein kinase C (Millar & Rozengurt, unpublished results).
Induction of the proto-oncogenes c-fos and c-myc Like PDGF and other growth factors, bombesins rapidly and transiently induce the expression of the cellular oncogenes c-fos and c-myc (Letterio et al., 1986; Palumbo et al., 1986; . Enhanced expression of c-fos occurs within minutes of bombesin addition and is followed by increased expression of c-myc.
The time-course and magnitude of these effects are similar to those induced by a saturating concentration of PDGF.
Bombesin-induced oncogene expression is markedly reduced by densitization of the protein kinase C pathway, implicating the activation of this phosphotransferase in the sequence of events leading to increased oncogene expression. However, because bombesin causes a marked increase in cytosolic Ca2+ and since elevation of Ca2+ by addition of the Ca2 + ionophore A23 187 enhances c-fos and c-myc induction by PBt2, it is likely that the induction of these cellular oncogenes by bombesin is mediated by the coordinated effects of Ca2+ mobilization and activation of protein kinase C (Figure 2) . However, additional signalling pathways may exist.
Effect ofpertussis toxin
In many cell types, pertussis toxin (which ADP-ribosylates and inactivates guanine nucleotide regulatory proteins) interferes with the receptor-mediated cleavage of PIP2 thereby inhibiting the production of IP3 and DAG. Letterio et al. (1986) reported that pertussis toxin blocks bombesin stimulation of DNA synthesis and induction of c-myc expression, an effect mediated at least in part by activation of protein kinase C. It was s-uggested that the bombesin receptor might be coupled to phospholipase C by a pertussis toxin-sensitive G protein. Recent experiments from our laboratory do not support this hypothesis. While pertussis toxin selectively inhibited bombesin-stimulated mitogenesis at an early stage in the action of the peptide, the toxin did not interfere with polyphosphoinositide breakdown, Ca2 + mobilization or activation of protein kinase C . We therefore concluded that the pertussis toxin-sensitive step in the stimulation of mitogenesis by bombesin and structurally related peptides can be dissociated from the phospholipase C signalling pathway.
Bombesin and lung cancer Lung cancer is the commonest fatal malignancy in the developed world and its incidence is increasing (Bailar & Smith, 1986) . SCLC constitutes 25% of these; it follows an aggressive course and, despite being initially chemosensitive, only 5% of patients survive 2 years after diagnosis (Spiro, 1985) . These tumours are associated with ectopic production of many different hormones, including vasopressin, adrenocorticotropin (ACTH) and bombesin. High concentrations of bombesins are present in specimens of SCLC and aresecreted by SCLC cell lines in vitro (Moody et al., 1981; Wood et al., 1981; Erisman et al., 1982) . The mRNA for GRP has been demonstrated in SCLC using synthetic oligodeoxyribonucleotide probes, and correlates well with immunoreactive GRP (Suzuki et al., 1987) . Cloned cDNAs to preproGRP have been prepared from SCLC and pulmonary carcinoid tumours but not other lung tumours.
The mRNA for preproGRP encodes a single copy of the GRP molecule and a 95 amino acid carboxy-terminal extension peptide, the actions of which are unknown (Spindel et al., 1984; Sausville et al., 1986; LebacqVerheyden et al., 1987) .
In view of the potent mitogenic activity of bombesins in the Swiss 3T3 model system, we suggested that secretion of these neuropeptides by SCLC could constitute part of an autocrine growth circuit (Rozengurt & Sinnett-Smith, 1983) . Bombesins are reported to stimulate SCLC grown in vitro Carney et al., 1987) . Cuttitta et al. (1985) demonstrated that monoclonal antibodies to bombesin inhibited the clonal growth of two SCLC cell lines in vitro and the growth of one of the lines as xenografts in nude mice. These findings strengthened the hypothesis of autocrine growth stimulation by bombesins in SCLC.
Bombesin antagonists
If bombesins are important in sustaining the unrestrained proliferation of SCLC, then the interruption of the putative autocrine growth loop with bombesin antagonists should suppress the growth of this tumour. An antagonist must bind to the specific receptor without producing the conformational changes which trigger the biological response.
Antagonists to neurotransmitters (such as acetylcholine), aand fl-adrenoceptors and histamines have had a large impact on clinical medicine, and synthetic peptide antagonists to parathyroid hormone and glucagon are under development (Rosenblatt, 1986) . Potent and specific bombesin antagonists could be crucial for testing the hypothesis of autocrine growth stimulation in SCLC.
[DArg', DPro2 D Trp7'9, Leu1 1] substance P The tachykinin substance P has minimal structural homology with bombesin (Table II) Unexpectedly, the substance P antagonist [DArg', DPro2, DTrp7'9, Leu' ] substance P (Peptide A in Table II ) was found to block the secretory effects of bombesin in pancreatic acinar cells (Jensen et al., 1984) and it was subsequently shown to antagonise the growth-promoting effects of bombesin in Swiss 3T3 cells (Zachary & Rozengurt, 1985a) . It has now been shown to block all the early events leading to bombesin-stimulated mitogenesis in these cells (Table III) . It also inhibits mitogenesis stimulated by vasopressin (Corps et al., 1985; .
SCLC cell lines grown in serum-free medium achieve 10-fold increase in number in about 12 days. Figure 3 (left) shows that the growth of H69 cells was suppressed by peptide A at 150 pM (a concentration that reversibly inhibits GRP-induced mitogenesis in Swiss 3T3 cells) but restored by 4, Mendoza et al., 1986; 5, Rozengurt & Sinnett-Smith, 1987; 6, Zachary & Rozengurt, 1986; 7, Corps et al., 1985. washing the cells and re-suspending them in serum-free medium. Figure 3 (right) demonstrates that the effect of the antagonist is concentration dependent. These results suggest a specific, non-toxic effect.
[DArg1, DPhe5, DTrp7 9, Leut1] substance P In order to identify more potent bombesin antagonists we have tested ten substance P antagonists at 50/iM (Table II) for their ability to inhibit GRP-stimulated mitogenesis in Swiss 3T3 cells. [DArg', DPhe5, DTrp7'9, Leu'1] substance P (Peptide D in Table II ) was clearly the most potent GRP antagonist. None of the other peptides was superior to peptide A but peptide D was consistently 5-fold more potent. None of these peptides exhibited agonist activity. Clearly the substitution of DPhe for Gln at position 5 is critical to the enhanced activity of peptide D.
Detailed studies of peptide D have now been completed (Woll & Rozengurt, 1988) . Its effects on the dose-response curve for GRP in an assay of DNA synthesis is shown in Figure 4 (left). The dose-response curve is shifted to the right but retains its shape, indicating that the effect of the antagonist is competitive and reversible. The dose-response curve for peptide D in the presence of GRP 3.6 nM is shown in figure 4 (right). Half-maximal inhibition of DNA synthesis was obtained with 22yM antagonist. (Dicker & Rozengurt, 1980; Rozengurt & Sinnett-Smith, 1983) . Right: Effects of varying concentrations of peptide D on DNA synthesis in the presence of 3.6 nM GRP and insulin I jigml-1. Like peptide A, peptide D exhibits specificity in blocking mitogenesis. It does not interfere with DNA synthesis stimulated by PBt2, cholera toxin with isobutylmethylxanthine, EGF or PDGF. Vasopressin-stimulated DNA synthesis, however, is markedly inhibited in a competitive and reversible manner ( Figure 5 ). Thus peptide D is an antagonist for at least three distinct neuropeptides whose effects are mediated through specific receptors. [125I] GRP and varying amounts of peptide D. After washing, they were incubated for 15 min with the cross-linking agent ethylene glycol bis (succinimidyl succinate) then solubilized and electrophoresed on a 10% polyacrylamide gel (inset) (Zachary & Rozengurt, 1987a Peptide D inhibits the growth of SCLC cell lines in vitro with half-maximal effect at 24 pM in the H69 cell line (Woll & Rozengurt, 1988 investigation into the mechanism of action of bombesins as mitogens. Detailed knowledge of these growth-regulatory pathways has led to formulation of hypotheses concerning the control of tumour growth in SCLC. These hypotheses will be subject to critical testing using synthetic bombesin antagonists such as [DArg', DPhe5, DTrp7'9, Leu11] (Hanley & Jackson, 1987; Masu et al., 1987 
